John L. Reagan

2.4k total citations
107 papers, 1.5k citations indexed

About

John L. Reagan is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, John L. Reagan has authored 107 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 40 papers in Hematology and 28 papers in Pathology and Forensic Medicine. Recurrent topics in John L. Reagan's work include Lymphoma Diagnosis and Treatment (26 papers), Acute Myeloid Leukemia Research (19 papers) and Chronic Lymphocytic Leukemia Research (11 papers). John L. Reagan is often cited by papers focused on Lymphoma Diagnosis and Treatment (26 papers), Acute Myeloid Leukemia Research (19 papers) and Chronic Lymphocytic Leukemia Research (11 papers). John L. Reagan collaborates with scholars based in United States, Italy and Poland. John L. Reagan's co-authors include Jorge J. Castillo, James W. Young, Joanna Mitri, Glenn Heller, Gudrun Ratzinger, Adam J. Olszewski, Nikhil K. Mull, Brigitte Sénéchal, Derek N.J. Hart and Adam Boruchov and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

John L. Reagan

93 papers receiving 1.5k citations

Peers

John L. Reagan
Akihiko Yokohama Japan
Taeko Ishii Japan
Silvia Park South Korea
Jae Ho Han South Korea
Nobuharu Fujii Japan
Serena Bugatti Italy
Ran Reshef United States
Mikaël Roussel France
Dennis Cooper United States
Siddhartha Ganguly United States
Akihiko Yokohama Japan
John L. Reagan
Citations per year, relative to John L. Reagan John L. Reagan (= 1×) peers Akihiko Yokohama

Countries citing papers authored by John L. Reagan

Since Specialization
Citations

This map shows the geographic impact of John L. Reagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John L. Reagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John L. Reagan more than expected).

Fields of papers citing papers by John L. Reagan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John L. Reagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John L. Reagan. The network helps show where John L. Reagan may publish in the future.

Co-authorship network of co-authors of John L. Reagan

This figure shows the co-authorship network connecting the top 25 collaborators of John L. Reagan. A scholar is included among the top collaborators of John L. Reagan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John L. Reagan. John L. Reagan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Reagan, John L., et al.. (2022). Thrombosis in COVID 2022: An Updated Narrative Review of Current Literature and Inpatient Management.. PubMed. 105(6). 36–40. 2 indexed citations
5.
Yaghi, Shadi, Ian J. Saldanha, Bashar Zaidat, et al.. (2022). Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis. Stroke. 53(10). 3014–3024. 21 indexed citations
6.
Martin, Peter, Nancy L. Bartlett, Julio C. Chávez, et al.. (2021). Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood. 139(8). 1147–1159. 21 indexed citations
7.
Pelcovits, Ari, et al.. (2021). Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia. Supportive Care in Cancer. 29(9). 5323–5327. 15 indexed citations
8.
Fast, Loren D., et al.. (2021). Murine Leukemia-Derived Extracellular Vesicles Elicit Antitumor Immune Response. Journal of Blood Medicine. Volume 12. 277–285. 4 indexed citations
9.
Zayac, Adam & John L. Reagan. (2021). Trials and Tribulations in the Frontline Treatment of Older Adults with Acute Myeloid Leukemia. SHILAP Revista de lepidopterología. 2(3). 515–544.
10.
Olszewski, Adam J., Anna Chorzalska, Diana O. Treaba, et al.. (2019). Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas. Blood. 134(Supplement_1). 2800–2800. 1 indexed citations
11.
Olszewski, Adam J., Thomas Ollila, & John L. Reagan. (2019). Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma. Blood. 134(Supplement_1). 2824–2824. 3 indexed citations
12.
Austin, Matthew, Peter J. Quesenberry, Corey E. Ventetuolo, Olin D. Liang, & John L. Reagan. (2019). Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis. Clinical Lymphoma Myeloma & Leukemia. 19(9). 593–597. 10 indexed citations
13.
14.
Chorzalska, Anna, Nagib Ahsan, Alexander Tepper, et al.. (2017). Map3k8/COT1/Tpl2 Drives Resistance to Bcr-Abl1 Inhibition through Activation of MEK-ERK and NF-Kb Pathways. Blood. 130. 2529–2529. 1 indexed citations
15.
Reagan, John L., et al.. (2017). Extracellular vesicles in leukemia. Leukemia Research. 64. 52–60. 46 indexed citations
16.
Chorzalska, Anna, Saad M. Khan, Diana O. Treaba, et al.. (2014). Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia. Leukemia. 28(11). 2165–2177. 11 indexed citations
17.
Tatto, Michael Del, Thomas Ng, Jason M. Aliotta, et al.. (2011). Marrow cell genetic phenotype change induced by human lung cancer cells. Experimental Hematology. 39(11). 1072–1080. 20 indexed citations
18.
Reagan, John L. & Jorge J. Castillo. (2011). Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. Expert Review of Anticancer Therapy. 11(2). 151–160. 11 indexed citations
19.
Yuan, Jianda, Jean‐Baptiste Latouche, John L. Reagan, et al.. (2005). Langerhans Cells Derived from Genetically Modified Human CD34+ Hemopoietic Progenitors Are More Potent Than Peptide-Pulsed Langerhans Cells for Inducing Antigen-Specific CD8+ Cytolytic T Lymphocyte Responses. The Journal of Immunology. 174(2). 758–766. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Akihiko Yokohama Breakdown of academic impact, for papers by Taeko Ishii Breakdown of academic impact, for papers by Silvia Park Breakdown of academic impact, for papers by Jae Ho Han Breakdown of academic impact, for papers by Nobuharu Fujii Breakdown of academic impact, for papers by Serena Bugatti Breakdown of academic impact, for papers by Ran Reshef Breakdown of academic impact, for papers by Mikaël Roussel Breakdown of academic impact, for papers by Dennis Cooper Breakdown of academic impact, for papers by Siddhartha Ganguly
Rankless by CCL
2026